# Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)

> **NCT05650411** · NA · RECRUITING · sponsor: **IGLESIAS Juan Fernando** · enrollment: 828 (estimated)

## Conditions studied

- Left Main Coronary Artery Stenosis

## Interventions

- **DEVICE:** LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India).
- **DRUG:** P2Y12 inhibitor-based SAPT after short DAPT
- **DRUG:** Conventional DAPT

## Key facts

- **NCT ID:** NCT05650411
- **Lead sponsor:** IGLESIAS Juan Fernando
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-26
- **Primary completion:** 2028-05-01
- **Final completion:** 2032-05-01
- **Target enrollment:** 828 (ESTIMATED)
- **Last updated:** 2026-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650411, "Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05650411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*